Join the Oncology Voice Network. Join for Free
Compliance 101-Most common issues and MSL-related gray areas
compliance in medical affairs MSL compliance FDA standards ethical collaboration professional development conferences

Compliance 101-Most common issues and MSL-related gray areas


Share This Article


Summary

In this episode, Jessica McLin and Melody Davis explore the intricacies of compliance and communication in medical affairs. Jessica shares her journey into entrepreneurship and discusses her work with Versant Learning Solutions. The conversation covers FDA standards, ethical collaboration with sales reps, and the importance of understanding company SOPs. They delve into strategies for navigating compliance gray areas and the role of training, especially in smaller companies. The episode also highlights the significance of professional development through conferences and the importance of leadership in enforcing compliance. Finally, they address key compliance rules and best practices for MSLs, including the Sunshine Act.

Today’s guests are Jessica McLin and Melody Davis of Versant Learning. We discuss MSL Compliance 101 and the most common issues and MSL-related gray areas.

In this episode we discuss:

  • Jessica and Melody intro
  • What Versant Learning does
  • Compliance and what people need to know
  • The most common gray areas to look out for
  • Where can an MSL find compliance information outside their current organization
  • The role of MSL Leadership in communicating compliance standards and how much of the effort lies on the MSL
  • The most important for the MSLs to keep in mind

Click for Source
compliance in medical affairs, MSL compliance, FDA standards, ethical collaboration, professional development conferences

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
How Should Medical Affairs Engage on Social Media
Partner Avatar MSL Talk: Tom Caravela

How Should Medical Affairs Engage on Social Media

Press Release
Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard
OVN Avatar OVN Staff

Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Explore OVN